Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia

Caocci, Giovanni; Atzeni, Sandra; Orrù, Nicola; Azzena, L; Martorana, L; Littera, Roberto; Ledda, Antonio; Nasa, Giorgio La

doi:10.1038/leu.2008.106

Cited by 35 publications

(27 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, c-kit, PDGFR-a, and PDGFR-b are important signal transduction modulators in testis organogenesis, Leydig cell differentiation, steroidogenesis, and spermatogenesis (2). Accordingly, different studies document several cases of circulating testosterone reduction and gynecomastia in male patients treated with imatinib or other multitargeted tyrosine kinase inhibitors, such as sunitinib and dasatinib, and hypothesize a mechanism by which the drugs reduce testosterone production through the block of PDGFR and c-kit in the testis (3)(4)(5). Earlier reports reported on pregnancy outcomes in male CML patients under imatinib treatment (6).…”

mentioning

confidence: 97%

Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty

Mariani¹,

Basciani²,

Fabbri³

et al. 2011

Fertility and Sterility

View full text Add to dashboard Cite

mentioning

confidence: 97%

Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty

Mariani¹,

Basciani²,

Fabbri³

et al. 2011

Fertility and Sterility

View full text Add to dashboard Cite

“…A single case of dasatinib-induced gynaecomastia in a 70-year-old man with ImI CML-CP is reported by Caocci et al 203 Dasatinib therapy was continued and tamoxifen introduced, with reportedly good effect in reducing tissue enlargement and discomfort.…”

mentioning

confidence: 99%

Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.

Rogers

Hoyle²,

Coon³

et al. 2012

Health Technol Assess

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTADasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . Th...

show abstract

“…Although studies of their effects have been limited, there appears to be reasonable evidence supporting the utility of tamoxifen (31)(32)(33)(34)(35) and some evidence that raloxifene is approximately as useful as tamoxifen (35). Neither tamoxifen nor raloxifene has been associated with significant side effects in the majority of patients (31)(32)(33)(34)(35). Tamoxifen has been used in doses of 10 -20 mg/d and raloxifene at a dose of 60 mg/d for 3-9 months.…”

Section: Therapymentioning

confidence: 94%

“…The overall response rate to tamoxifen has varied from 50 -80%, although reported side effects have been few (31)(32)(33)(34)(35). It has not yet been clearly established whether tamoxifen and raloxifene are of equal benefit, although it seems reasonably clear that both are more effective than aromatase inhibitors (36,45,46).…”

Section: Controversies and Areas Of Uncertaintymentioning

confidence: 94%

Approach to the Patient with Gynecomastia

Carlson

2011

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

Gynecomastia is a common and sometimes distressing condition that may occur in males of all ages. Although most cases have benign causes and many are self-limited, male breast enlargement may also be a sign of underlying systemic disease or drug toxicity. Although rare, male breast cancer must also be considered in the differential diagnosis. A careful diagnostic evaluation should be pursued, tailored to the individual patient's circumstances. Treatment may include reassurance, medication, or surgery.

show abstract

Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia

Cited by 35 publications

References 8 publications

Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty

Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty

Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.

Approach to the Patient with Gynecomastia

Contact Info

Product

Resources

About